Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15867032 | 0.86 | VNN1 (0.56) | TSHRMRGPRX4AURKATPX2MAPT | |
| SCHEMBL17272798 | 0.85 | TSHR (0.59) | TSHRMRGPRX4ALDH1A1MAPTHPGD | |
| SCHEMBL4089965 | 0.85 | VCAM1 (0.47) | TSHRMRGPRX4AURKATPX2MAPT | |
| SCHEMBL24494667 | 0.83 | VCAM1 (0.46) | TSHRMRGPRX4AURKATPX2ALDH1A1 | |
| SCHEMBL8139092 | 0.83 | VCAM1 (0.46) | MRGPRX4AURKATPX2VCAM1VNN1 | |
| SCHEMBL29472005 | 0.82 | ALDH1A1 (0.59) | TSHRMRGPRX4ALDH1A1MAPTHPGD | |
| SCHEMBL4844022 | 0.82 | ALDH1A1 (0.59) | TSHRMRGPRX4ALDH1A1MAPTHPGD | |
| SCHEMBL4155009 | 0.81 | VCAM1 (0.45) | TSHRMRGPRX4AURKATPX2ALDH1A1 | |
| SCHEMBL28105888 | 0.81 | TSHR (0.59) | TSHRMRGPRX4ALDH1A1MAPTSRD5A2 | |
| SCHEMBL8060674 | 0.80 | VNN1 (0.45) | TSHRMRGPRX4AURKATPX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-20250011326-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2025-01-09 | — | — | US | disclosed |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-1434811-A | Novel P2X for use in the treatment of inflammatory, immune or cardiovascular diseases7Receptor antagonists | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
| EP-0808318-B1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5597823-A | TREATING BENIGN PROSTATIC HYPERPLASIA | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | disclosed |
| WO-1996022992-A1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |
| US-4871387-A | Pyri(mi)dyl-oxy-and -thio-benzoic acid derivatives useful as herbicides and plant growth regulants | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| EP-0279698-A2 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-08-24 | — | — | EP | disclosed |
| EP-0226837-A2 | Pyri(mi)dyloxy and -thiobenzoic acid derivatives | BAYER AG (DE) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | TSHR 3584/4885MRGPRX4 2808/4885AURKA 1017/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TSHR 951/4885MRGPRX4 251/4885AURKA 2905/4885 |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | TSHR 690/4885MRGPRX4 24/4885AURKA 3894/4885 |
| US-20240317752-A1 | 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES | TYMP, DPYD, PNP | TSHR 3688/4885MRGPRX4 921/4885AURKA 2057/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | TSHR 1133/4885MRGPRX4 277/4885AURKA 3162/4885 |
| US-20250011326-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | HAVCR2, HCCS, HDGF | TSHR 3425/4885MRGPRX4 2983/4885AURKA 1565/4885 |
| US-20260001893-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, NCOR1, NCOR2 | TSHR 40/4885MRGPRX4 273/4885AURKA 3512/4885 |
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | TSHR 1122/4885MRGPRX4 243/4885AURKA 2929/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | TSHR 71/4885MRGPRX4 173/4885AURKA 4772/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | TSHR 951/4885MRGPRX4 251/4885AURKA 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.